
CAS 1628805-46-8
:Formula:C23H22F4N6O2
InChI:InChI=1S/C23H22F4N6O2/c1-12-8-17(30-10-16(12)15-4-6-28-19(9-15)23(25,26)27)14(3)31-21-29-7-5-20(32-21)33-18(13(2)24)11-35-22(33)34/h4-10,13-14,18H,11H2,1-3H3,(H,29,31,32)/t13-,14-,18+/m0/s1
InChI key:DCGDPJCUIKLTDU-SUNYJGFJSA-N
SMILES:CC1=CC(=NC=C1C2=CC(=NC=C2)C(F)(F)F)[C@H](C)NC3=NC=CC(=N3)N4[C@H](COC4=O)[C@H](C)F
Filter by
Purity percentage
0
100
|
0
|
50
|
90
|
95
|
100
Found 6 products.
- Lower prices
- Higher prices
- Lower purities
- Higher purities
- Faster estimated delivery
IDH-305
CAS:IDH-305: Oral, mutation-specific IDH1 inhibitor, 200x selective for R132 mutants; IC50: 27/28/6.14 nM for R132H/C/WT.Formula:C23H22F4N6O2Purity:99.68%Color and Shape:SolidMolecular weight:490.4534(R)-4-((S)-1-Fluoroethyl)-3-(2-(((S)-1-(4-methyl-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one
CAS:(R)-4-((S)-1-Fluoroethyl)-3-(2-(((S)-1-(4-methyl-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-oneFormula:C23H22F4N6O2Purity:98%Molecular weight:490.45(4R)-4-[(1S)-1-fluoroethyl]-3-(2-{[(1S)-1-[4-methyl-2′-(trifluoromethyl)-[3,4′-bipyridin]-6-yl]ethyl]amino}pyrimidin-4-yl)-1,3-oxazolidin-2-one
CAS:Purity:98%Molecular weight:490.4630127IDH 305
CAS:IDH 305 is a retinoic acid that is used in the treatment of intrahepatic cholangiocarcinoma (ICC). It has been shown to inhibit cancer cell growth in vitro and in vivo. Retinoic acid binds to cellular retinoic acid receptors, which activate transcription factors that regulate gene expression. The activity of IDH 305 may be due to its ability to inhibit glucose transporters, leading to decreased uptake of glucose into cells and inhibition of histone methylation and DNA synthesis.Formula:C23H22F4N6O2Purity:Min. 95%Molecular weight:490.45 g/mol





